BR112022014627A2 - Vacina contra coronavírus - Google Patents
Vacina contra coronavírusInfo
- Publication number
- BR112022014627A2 BR112022014627A2 BR112022014627A BR112022014627A BR112022014627A2 BR 112022014627 A2 BR112022014627 A2 BR 112022014627A2 BR 112022014627 A BR112022014627 A BR 112022014627A BR 112022014627 A BR112022014627 A BR 112022014627A BR 112022014627 A2 BR112022014627 A2 BR 112022014627A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- vaccine against
- corona virus
- coronavirus
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
VACINA CONTRA CORONAVÍRUS. A presente invenção refere-se a um ácido nucleico adequado para uso no tratamento ou profilaxia de uma infecção por um coronavírus, preferencialmente com um Coronavírus SARS-CoV-2, ou um distúrbio relacionado a tal infecção, preferencialmente COVID-19. A presente invenção também é dirigida a composições, polipeptídeos e vacinas. As composições e vacinas compreendem preferencialmente pelo menos uma das referidas sequências de ácido nucleico, preferencialmente sequências de ácido nucleico em associação com uma nanopartícula lipídica (LNP). A invenção também é direcionada ao primeiro e segundo usos médicos do ácido nucleico, à composição, ao polipeptídeo, à combinação, à vacina e ao kit, e a métodos de tratamento ou prevenção de uma infecção por coronavírus, preferencialmente uma infecção por Coronavírus.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2020052775 | 2020-02-04 | ||
EP2020059687 | 2020-04-03 | ||
EP2020065091 | 2020-05-29 | ||
EP2020079831 | 2020-10-22 | ||
EP2020079973 | 2020-10-23 | ||
EP2020080713 | 2020-11-02 | ||
US202063112106P | 2020-11-10 | 2020-11-10 | |
US202063113159P | 2020-11-12 | 2020-11-12 | |
US202063119390P | 2020-11-30 | 2020-11-30 | |
US202063129395P | 2020-12-22 | 2020-12-22 | |
PCT/EP2021/052455 WO2021156267A1 (en) | 2020-02-04 | 2021-02-03 | Coronavirus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022014627A2 true BR112022014627A2 (pt) | 2022-09-27 |
Family
ID=74586987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022014627A BR112022014627A2 (pt) | 2020-02-04 | 2021-02-03 | Vacina contra coronavírus |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP4147717A1 (pt) |
JP (1) | JP2023513502A (pt) |
KR (1) | KR20220144416A (pt) |
CN (1) | CN116113430A (pt) |
AU (1) | AU2021216658A1 (pt) |
BR (1) | BR112022014627A2 (pt) |
CA (1) | CA3160511A1 (pt) |
DE (4) | DE202021003575U1 (pt) |
IL (1) | IL293571A (pt) |
MX (1) | MX2022009460A (pt) |
WO (1) | WO2021156267A1 (pt) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
FI3864163T3 (fi) | 2018-10-09 | 2024-05-03 | Univ British Columbia | Koostumukset ja järjestelmät, joihin sisältyvät transfektiokompetentit vesikkelit, joissa ei ole orgaanisia liuottimia eikä pesuaineita, sekä niihin liittyvät menetelmät |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
GB202307565D0 (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
BR112022024248A2 (pt) * | 2020-05-29 | 2023-10-10 | CureVac SE | Vacinas de combinação à base de ácido nucleico |
US20220016268A1 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
US20230322863A1 (en) * | 2020-08-24 | 2023-10-12 | Phylex Biosciences, Inc. | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection |
CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
AU2022208057A1 (en) * | 2021-01-15 | 2023-08-03 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
AU2022207495A1 (en) * | 2021-01-15 | 2023-08-03 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
CN113150085B (zh) * | 2021-04-27 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的组合物 |
WO2023015332A1 (en) * | 2021-08-11 | 2023-02-16 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Vaccine antigen |
WO2023018384A1 (en) * | 2021-08-13 | 2023-02-16 | Chulalongkorn University | A vaccine composition against coronavirus infection |
WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
CN115710191A (zh) * | 2021-08-23 | 2023-02-24 | 广州谷森制药有限公司 | 新型阳离子脂质化合物 |
CN115710193A (zh) * | 2021-08-23 | 2023-02-24 | 广州谷森制药有限公司 | 新型阳离子脂质化合物 |
WO2023025031A1 (zh) * | 2021-08-23 | 2023-03-02 | 北京百普赛斯生物科技股份有限公司 | 用于疫苗或中和抗体测试中的SARS-CoV-2病毒S蛋白中和表位 |
EP4392140A1 (en) | 2021-08-24 | 2024-07-03 | BioNTech SE | In vitro transcription technologies |
WO2023030476A1 (en) * | 2021-09-02 | 2023-03-09 | Medigen Vaccine Biologics Corporation | Immunogenic compositions and methods for immunization against variants of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
CN117940158A (zh) | 2021-09-03 | 2024-04-26 | 库瑞瓦格欧洲公司 | 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒 |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
WO2023039540A2 (en) * | 2021-09-10 | 2023-03-16 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
CN113896774B (zh) * | 2021-09-18 | 2023-07-28 | 中国医学科学院医学生物学研究所 | 一种重组蛋白k-s及其制备方法和应用 |
CN115850686A (zh) * | 2021-09-27 | 2023-03-28 | 广州谷森制药有限公司 | 新型氘代peg脂质化合物、其制备方法、组合物和应用 |
CA3132191A1 (en) * | 2021-09-28 | 2023-03-28 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
WO2023057444A1 (en) * | 2021-10-05 | 2023-04-13 | Sanofi | METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME |
CA3234656A1 (en) * | 2021-10-06 | 2023-04-13 | Diosynvax Ltd | Coronavirus vaccines |
KR20230053998A (ko) * | 2021-10-15 | 2023-04-24 | (주)지노믹트리 | mRNA 발현을 위한 유전자 구조체 |
WO2023064907A1 (en) * | 2021-10-15 | 2023-04-20 | Yale University | Compositions and methods for vaccination against pathogenic coronavirus species and variants |
CN118302189A (zh) * | 2021-10-21 | 2024-07-05 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
WO2023096963A1 (en) * | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
CA3238735A1 (en) * | 2021-11-24 | 2023-06-01 | Jennifer A. Nelson | Immunogenic compositions and their uses |
CA3239266A1 (en) * | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
WO2023121264A1 (ko) * | 2021-12-20 | 2023-06-29 | 아이진 주식회사 | 변이 sars-cov-2 백신 조성물 및 이의 용도 |
GB202119115D0 (en) * | 2021-12-30 | 2022-02-16 | Fondo Ricerca Medica S R I | Vaccine |
RU2769224C1 (ru) * | 2021-12-30 | 2022-03-29 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Рекомбинантные вирусоподобные частицы для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 |
WO2023133684A1 (en) * | 2022-01-11 | 2023-07-20 | Peking University | Circular rna vaccines against sars-cov-2 variants and methods of use thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
CN116731192A (zh) * | 2022-03-01 | 2023-09-12 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
WO2023166061A1 (en) * | 2022-03-02 | 2023-09-07 | ISR Immune System Regulation Holding AB (publ) | Vaccine composition comprising an antigen and a tlr3 agonist |
CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
TW202400793A (zh) * | 2022-04-29 | 2024-01-01 | 美商薩納度生物公司 | 增強免疫力之方法 |
WO2023220693A1 (en) * | 2022-05-12 | 2023-11-16 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
WO2024014770A1 (ko) * | 2022-07-14 | 2024-01-18 | 엠큐렉스 주식회사 | mRNA 백신 및 치료제의 제조를 위한 변형된 RNA |
US11898186B1 (en) * | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
CN116621990B (zh) * | 2022-09-06 | 2024-01-02 | 广东药科大学 | 一种SARS-CoV-2疫苗抗原的制备方法及其应用 |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024073848A1 (en) * | 2022-10-04 | 2024-04-11 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
CN117253577B (zh) * | 2023-11-17 | 2024-03-12 | 四川省大数据技术服务中心 | 一种多维卫生健康数据集成处理系统 |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR702E (fr) | 1903-02-28 | Caille Charles | Appareil stérilisateur pour l'eau ou d'autres liquides | |
US2780312A (en) | 1953-11-30 | 1957-02-05 | Daniel I Glossbrenner | Electro-mechanical lubricant distributor |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
EP2428568B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
AU2003295366B2 (en) | 2002-11-04 | 2011-11-24 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
EP1809753A1 (en) | 2004-11-02 | 2007-07-25 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
CA3044134A1 (en) | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
ES2543730T3 (es) | 2008-06-12 | 2015-08-21 | Expres2Ion Biotechnologies Aps | Sistema mejorado de expresión de proteína |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
KR102344392B1 (ko) | 2008-11-10 | 2021-12-28 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
NZ621981A (en) | 2009-05-05 | 2015-09-25 | Tekmira Pharmaceuticals Corp | Lipid compositions |
EA201791744A3 (ru) | 2009-06-10 | 2018-07-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | NEW CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR ADMINISTRATION OF OLIGONUCLEOTIDES |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
US9254327B2 (en) | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
DK2575764T3 (en) | 2010-06-03 | 2017-08-07 | Alnylam Pharmaceuticals Inc | BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS |
EP2575767B1 (en) | 2010-06-04 | 2017-01-04 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
ES2888231T3 (es) | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
JP2013545723A (ja) | 2010-09-30 | 2013-12-26 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチドの送達のための低分子量カチオン性脂質 |
JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
DK2635265T3 (en) | 2010-11-05 | 2018-07-16 | Sirna Therapeutics Inc | New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNA送達のための脂質ナノ粒子組成物および方法 |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
US8969545B2 (en) | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
AU2012328570B2 (en) | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
ES2921724T1 (es) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Lípidos biodegradables para la administración de agentes activos |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
MX358706B (es) | 2012-03-27 | 2018-08-31 | Curevac Ag | Moleculas de acido nucleico artificiales que comprenden un top 5´utr. |
ES2680595T3 (es) | 2013-03-14 | 2018-09-10 | Translate Bio, Inc. | Evaluación cuantitativa para eficacia de ARN mensajero para tapar |
CN105209633A (zh) | 2013-03-14 | 2015-12-30 | 夏尔人类遗传性治疗公司 | 信使rna加帽效率的定量评估 |
EP3060257B1 (en) | 2013-10-22 | 2021-02-24 | Translate Bio, Inc. | Lipid formulations for delivery of messenger rna |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
WO2015074085A1 (en) | 2013-11-18 | 2015-05-21 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for rna delivery |
SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
BR112016026980B1 (pt) | 2014-06-10 | 2022-05-03 | Curevac Real Estate Gmbh | Método para sintetizar uma molécula de rna de uma dada sequência |
CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20180085391A1 (en) | 2014-08-08 | 2018-03-29 | Modernatx, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
US9620868B2 (en) | 2014-10-27 | 2017-04-11 | Matthew Wootton | Compact electrical connection system |
ES2791152T3 (es) | 2014-12-12 | 2020-11-03 | Curevac Ag | Moléculas de ácido nucleico artificiales para una expresión proteica mejorada |
EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
SG11201708867UA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Immobilized poly(n)polymerase |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
EP3916091A3 (en) | 2015-05-20 | 2022-03-30 | CureVac AG | Dry powder composition comprising long-chain rna |
CN107873055B (zh) | 2015-05-29 | 2021-09-17 | 库瑞瓦格房地产有限公司 | 包括至少一个切向流过滤步骤的产生和纯化rna的方法 |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
JP7304155B2 (ja) | 2015-08-28 | 2023-07-06 | キュアバック エスイー | 人工核酸分子 |
ES2968391T3 (es) | 2015-09-21 | 2024-05-09 | Trilink Biotechnologies Llc | Cebadores oligonucleotídicos iniciadores con caperuza para sintetizar ARN con caperuza 5' |
US20190218546A1 (en) | 2015-10-16 | 2019-07-18 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
EP3362460A1 (en) | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
MA46023A (fr) | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
AU2016343803B2 (en) | 2015-10-28 | 2021-04-29 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20180312545A1 (en) | 2015-11-09 | 2018-11-01 | Curevac Ag | Optimized nucleic acid molecules |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
US9834510B2 (en) | 2015-12-30 | 2017-12-05 | Arcturus Therapeutics, Inc. | Aromatic ionizable cationic lipid |
KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
EP3529255A1 (en) | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
WO2018081318A1 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
KR20190093816A (ko) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
US11141476B2 (en) * | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
KR20200071081A (ko) | 2017-10-19 | 2020-06-18 | 큐어백 아게 | 신규 인공 핵산 분자 |
EP3794008A1 (en) | 2018-05-16 | 2021-03-24 | Translate Bio, Inc. | Ribose cationic lipids |
WO2019226925A1 (en) | 2018-05-24 | 2019-11-28 | Translate Bio, Inc. | Thioester cationic lipids |
JP2021525743A (ja) | 2018-05-30 | 2021-09-27 | トランスレイト バイオ, インコーポレイテッド | リン酸エステルカチオン性脂質 |
WO2019232208A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
WO2019232095A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Vitamin cationic lipids |
WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
CN109787464B (zh) | 2019-03-27 | 2022-07-12 | 阳光电源股份有限公司 | 一种拓扑单元并联保护方法、装置及系统 |
JP2023511633A (ja) | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスrnaワクチン |
-
2021
- 2021-02-03 CA CA3160511A patent/CA3160511A1/en active Pending
- 2021-02-03 DE DE202021003575.3U patent/DE202021003575U1/de not_active Withdrawn - After Issue
- 2021-02-03 MX MX2022009460A patent/MX2022009460A/es unknown
- 2021-02-03 JP JP2022547273A patent/JP2023513502A/ja active Pending
- 2021-02-03 WO PCT/EP2021/052455 patent/WO2021156267A1/en unknown
- 2021-02-03 AU AU2021216658A patent/AU2021216658A1/en active Pending
- 2021-02-03 EP EP22191103.5A patent/EP4147717A1/en active Pending
- 2021-02-03 DE DE202021004123.0U patent/DE202021004123U1/de not_active Withdrawn - After Issue
- 2021-02-03 BR BR112022014627A patent/BR112022014627A2/pt unknown
- 2021-02-03 EP EP21704439.5A patent/EP3886897A1/en active Pending
- 2021-02-03 DE DE112021000012.8T patent/DE112021000012B4/de active Active
- 2021-02-03 KR KR1020227028435A patent/KR20220144416A/ko active Search and Examination
- 2021-02-03 CN CN202180010211.1A patent/CN116113430A/zh active Pending
- 2021-02-03 DE DE202021004130.3U patent/DE202021004130U1/de active Active
- 2021-02-03 IL IL293571A patent/IL293571A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3160511A1 (en) | 2021-08-12 |
MX2022009460A (es) | 2022-12-16 |
CN116113430A (zh) | 2023-05-12 |
DE202021003575U1 (de) | 2022-01-17 |
DE112021000012B4 (de) | 2023-08-31 |
EP4147717A1 (en) | 2023-03-15 |
DE202021004130U1 (de) | 2022-10-26 |
JP2023513502A (ja) | 2023-03-31 |
KR20220144416A (ko) | 2022-10-26 |
IL293571A (en) | 2022-08-01 |
EP3886897A1 (en) | 2021-10-06 |
DE202021004123U1 (de) | 2022-10-26 |
DE112021000012T5 (de) | 2021-11-18 |
AU2021216658A1 (en) | 2022-06-23 |
WO2021156267A1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014627A2 (pt) | Vacina contra coronavírus | |
BR112023012303A2 (pt) | Vacina de rna contra variantes de sars-cov-2 | |
UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
BR112018016755A2 (pt) | vacina contra o vírus da zica | |
BR112022026733A2 (pt) | Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas | |
WO2019193183A3 (en) | Novel yellow fever nucleic acid molecules for vaccination | |
MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112023020600A2 (pt) | Método para tratar ou prevenir uma infecção, e, uso de um composto | |
BR0011737A (pt) | Vacina de poxvìrus recombinante de circovìrus de porcino | |
BR112019009133A2 (pt) | vacina contra o parvovírus suíno | |
BR112021021637A2 (pt) | Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório | |
WO2022043551A3 (en) | Multivalent nucleic acid based coronavirus vaccines | |
BR112022002202A2 (pt) | Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
BR0111366A (pt) | Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv) | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112015030355A8 (pt) | uso de uma proteína ou um polipeptídeo de adenilil ciclase tipo 6 (ac6) incompetente com a adenosina monofosfato cíclico (incompetente com camp) ou um gene ou ácido nucléico que codifica ac6mut, e, formulação | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
BR112022016507A2 (pt) | Vacinas contra o coronavírus e métodos de uso | |
BR0316244A (pt) | Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo | |
BR112022026408A2 (pt) | Combinação vacinal contra infecção pelo vírus sincicial respiratório | |
BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia |